Randomized trial of standard therapy with or without poly I:C in patients with superficial bladder cancer.
Thirty-two patients with superficial urinary bladder tumors were stratified for four variables and randomized after complete transurethral resection and/or fulguration of tumor to receive standard therapy with or without intravenous Poly I:C. Cystoscopies were performed at three- to four-month intervals for up to 48 months. While there was no statistically significant difference in the tumor recurrence rates in the two groups during the first year, a significant increase (P = 0.003) in survival at four years was observed between the Poly I:C group and the control group. The difficulties in evaluating the efficacy of anti-neoplastic agents in the treatment of superficial bladder tumors are discussed.
D000368:Aged; D002278:Carcinoma in Situ / Q000188:drug therapy; D002986:Clinical Trials as Topic; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D011070:Poly I-C / Q000009:adverse effects / Q000627:therapeutic use*; D011897:Random Allocation; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
D011070:Poly I-C